Search

Your search keyword '"Eicher, Jean Christophe"' showing total 306 results
Start Over Author "Eicher, Jean Christophe"
306 results on '"Eicher, Jean Christophe"'

1. Prognostic value of cardiovascular magnetic resonance T1 mapping and extracellular volume fraction in nonischemic dilated cardiomyopathy

Author

Cadour, Farah, Quemeneur, Morgane, Biere, Loic, Donal, Erwan, Bentatou, Zakarya, Eicher, Jean-Christophe, Roubille, François, Lalande, Alain, Giorgi, Roch, Rapacchi, Stanislas, Cortaredona, Sébastien, Tradi, Farouk, Bartoli, Axel, Willoteaux, Serge, Delahaye, François, Biene, Stephanie M., Mangin, Lionel, Ferrier, Nadine, Dacher, Jean-Nicolas, Bauer, Fabrice, Leurent, Guillaume, Lentz, Pierre-Axel, Kovacsik, Hélène, Croisille, Pierre, Thuny, Franck, Bernard, Monique, Guye, Maxime, Furber, Alain, Habib, Gilbert, and Jacquier, Alexis

Published
2023
Full Text
View/download PDF

2. Transthyretin amyloid cardiomyopathy in France: A cross-sectional multi-centre study (333 patients)

Author

Damy, Thibaud, Donal, Erwan, Lairez, Olivier, Eicher, Jean-Christophe, Karoubi, Mounira, Trochu, Jean-Noël, Inamo, Jocelyn, Habib, Gilbert, Roubille, François, Hagège, Albert, Morio, Flore, Cariou, Eve, Adda, Jérôme, Algalarrondo, Vincent, Coste, Agathe, Bartoli, Mathilde, Rudant, Jérémie, Salvi, Lara, Francou, Bruno, Guiochon-Mantel, Anne, Adams, David, Antoine, Jean-Christophe, Attarian, Shahram, Cintas, Pascal, Morales, Raul Juntas, Lagrange, Emmeline, Magy, Laurent, Mallaret, Martial, Péréon, Yann, Petiot, Philippe, Cauquil, Cécile, Labeyrie, Céline, Echaniz-Laguna, Andoni, Sole, Guilhem, Tard, Céline, Oghina, Silvia, Charron, Philippe, and Slama, Michel

Published
2024
Full Text
View/download PDF

3. Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction

Author

Litwin, Sheldon E., Komtebedde, Jan, Hu, Mo, Burkhoff, Daniel, Hasenfuß, Gerd, Borlaug, Barry A., Solomon, Scott D., Zile, Michael R., Mohan, Rajeev C., Khawash, Rami, Sverdlov, Aaron L., Fail, Peter, Chung, Eugene S., Kaye, David M., Blair, John, Eicher, Jean-Christophe, Hummel, Scott L., Zirlik, Andreas, Westenfeld, Ralf, Hayward, Christopher, Gorter, Thomas M., Demers, Catherine, Shetty, Ranjith, Lewis, Gregory, Starling, Randall C., Patel, Sanjay, Gupta, Deepak K., Morsli, Hakim, Penicka, Martin, Cikes, Maja, Gustafsson, Finn, Silvestry, Frank E., Rowin, Ethan J., Cutlip, Donald E., Leon, Martin B., Kitzman, Dalane W., Kleber, Franz X., and Shah, Sanjiv J.

Published
2023
Full Text
View/download PDF

7. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

Author

Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Chung, Eugene, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean-Christophe, Fail, Peter, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, Hass, Moritz, Hausleiter, Jorg, Hayward, Christopher, Hickey, Gavin, Hummel, Scott, Hussain, Imad, Isnard, Richard, Izumi, Chisato, Jondeau, Guillaume, Juneman, Elizabeth, Kinugawa, Koichiro, Kipperman, Robert, Krakowiak, Bartek, Krim, Selim, Larned, Joshua, Lewis, Gregory, Lipsic, Erik, Magalski, Anthony, Mazimba, Sula, Mazurek, Jeremy, McGrady, Michele, Mckenzie, Scott, Mehta, Shamir, Mignone, John, Morsli, Hakim, Nair, Ajith, Noel, Thomas, Orford, James, Parikh, Kishan, Patterson, Tiffany, Penicka, Martin, Petrie, Mark, Pieske, Burkert, Post, Martijn, Raake, Philip, Romero, Alicia, Ryan, John, Saito, Yoshihiko, Sakamoto, Takafumi, Sakata, Yasushi, Samara, Michael, Satya, Kumar, Sindone, Andrew, Starling, Randall, Trochu, Jean-Noël, Upadhya, Bharathi, van der Heyden, Jan, van Empel, Vanessa, Varma, Amit, Vest, Amanda, Wengenmayer, Tobias, Westenfeld, Ralf, Westermann, Dirk, Yamamoto, Kazuhiro, Zirlik, Andreas, Shah, Sanjiv J, Borlaug, Barry A, Chung, Eugene S, Cutlip, Donald E, Debonnaire, Philippe, Fail, Peter S, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M, Litwin, Sheldon E, Lurz, Philipp, Massaro, Joseph M, Mohan, Rajeev C, Ricciardi, Mark J, Solomon, Scott D, Sverdlov, Aaron L, Swarup, Vijendra, van Veldhuisen, Dirk J, Winkler, Sebastian, and Leon, Martin B

Published
2022
Full Text
View/download PDF

8. Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study.

Author

Fauvel, Charles, Damy, Thibaud, Berthelot, Emmanuelle, Bauer, Fabrice, Eicher, Jean-Christophe, Groote, Pascal de, Trochu, Jean-Noël, Picard, François, Renard, Sébastien, Bouvaist, Hélène, Logeart, Damien, Roubille, François, Sitbon, Olivier, and Lamblin, Nicolas

Subjects
PULMONARY hypertension, PULMONARY artery, HEART failure, VASCULAR resistance, PROGNOSIS
Abstract

Background and Aims Based on retrospective studies, the 2022 European guidelines changed the definition of post-capillary pulmonary hypertension (pcPH) in heart failure (HF) by lowering the level of mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR). However, the impact of this definition and its prognostic value has never been evaluated prospectively. Methods Stable left HF patients with the need for right heart catheterization were enrolled from 2010 to 2018 and prospectively followed up in this multicentre study. The impact of the successive pcPH definitions on pcPH prevalence and subgroup [i.e. isolated (IpcPH) vs. combined pcPH (CpcPH)] was evaluated. Multivariable Cox regression analysis was used to assess the prognostic value of mPAP and PVR on all-cause death or hospitalization for HF (primary outcome). Results Included were 662 HF patients were (median age 63 years, 60% male). Lowering mPAP from 25 to 20 mmHg resulted in +10% increase in pcPH prevalence, whereas lowering PVR from 3 to 2 resulted in +60% increase in CpcPH prevalence (with significant net reclassification improvement for the primary outcome). In multivariable analysis, both mPAP and PVR remained associated with the primary outcome [hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.00–1.03, P =.01; HR 1.07, 95% CI 1.00–1.14, P =.03]. The best PVR threshold associated with the primary outcome was around 2.2 WU. Using the 2022 definition, pcPH patients had worse survival compared with HF patients without pcPH (log-rank, P =.02) as well as CpcPH compared with IpcPH (log-rank, P =.003). Conclusions This study is the first emphasizing the impact of the new pcPH definition on CpcPH prevalence and validating the prognostic value of mPAP > 20 mmHg and PVR > 2 WU among HF patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Phenotype/Genotype Relationship in Left Ventricular Noncompaction: Ion Channel Gene Mutations Are Associated With Preserved Left Ventricular Systolic Function and Biventricular Noncompaction: Phenotype/Genotype of Noncompaction

Author

Cambon-Viala, Marie, Gerard, Hilla, Nguyen, Karine, Richard, Pascale, Ader, Flavie, Pruny, Jean-François, Donal, Erwan, Eicher, Jean-Christophe, Huttin, Olivier, Selton-Suty, Christine, Raud-Raynier, Pascale, Jondeau, Guillaume, Mansencal, Nicolas, Sawka, Caroline, Casalta, Anne-Claire, Michel, Nicolas, Donghi, Valeria, Martel, Hélène, Faivre, Laurence, Charron, Philippe, and Habib, Gilbert

Published
2021
Full Text
View/download PDF

14. Time to blood culture positivity: An independent predictor of infective endocarditis and mortality in patients with Staphylococcus aureus bacteraemia

Author

Chirouze, Catherine, Curlier, Elodie, Descottes-Genon, Cécile, Hoen, Bruno, Patry, Isabelle, Vettoretti, Lucie, Chavanet, Pascal, Eicher, Jean-Christophe, Gohier-Treuvelot, Sandrine, Greusard, Marie-Christine, Neuwirth, Catherine, Péchinot, André, Piroth, Lionel, Célard, Marie, Cornu, Catherine, Delahaye, François, Hadid, Malika, Rausch, Pascale, Coma, Audrey, Galtier, Florence, Géraud, Philippe, Jean-Pierre, Hélène, Le Moing, Vincent, Sportouch, Catherine, Reynes, Jacques, Aissa, Nejla, Doco-Lecompte, Thanh, Goehringer, François, Keil, Nathalie, Letranchant, Lorraine, Malela, Hepher, May, Thierry, Selton-Suty, Christine, Bedos, Nathalie, Lavigne, Jean-Philippe, Lechiche, Catherine, Sotto, Albert, Duval, Xavier, Habensus, Emila Ilic, Iung, Bernard, Leport, Catherine, Longuet, Pascale, Ruimy, Raymond, Bellissant, Eric, Donnio, Pierre-Yves, Le Gac, Fabienne, Michelet, Christian, Revest, Matthieu, Tattevin, Pierre, Thebault, Elise, Alla, François, Braquet, Pierre, Erpelding, Marie-Line, Minary, Laetitia, Tubiana, Sarah, Bès, Michèle, Etienne, Jérôme, Lelekov-Boissard, Taissia, Tristan, Anne, Vandenesch, François, Van Belkum, Alex, Rivadeneira, Fernando, Vanwamel, Willem, Barbas, Sandrine, Delonca, Christine, Sussmuth, Virginie, Verchère, Anne, Siméon, S., Le Moing, V., Tubiana, S., Duval, X., Fournier, D., Lavigne, J.-P., Erpelding, M.-L., Gustave, C.-A., Desage, S., Chirouze, C., Vandenesch, F., and Tattevin, P.

Published
2019
Full Text
View/download PDF

15. Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP‐HF II trial.

Author

Litwin, Sheldon E., Komtebedde, Jan, Seidler, Tim, Borlaug, Barry A., Winkler, Sebastian, Solomon, Scott D., Eicher, Jean‐Christophe, Mazimba, Sula, Khawash, Rami, Sverdlov, Aaron L., Hummel, Scott L., Bugger, Heiko, Boenner, Florian, Hoendermis, Elke, Cikes, Maja, Demers, Catherine, Silva, Guillherme, van Empel, Vanessa, Starling, Randall C., and Penicka, Martin

Subjects
VENTRICULAR ejection fraction, HEART failure, OBESITY, VASCULAR resistance, CARDIAC output, BODY mass index
Abstract

Aims: Obesity is causally related to the development of heart failure with preserved ejection fraction (HFpEF) but complicates the diagnosis and treatment of this disorder. We aimed to determine the relationship between severity of obesity and clinical, echocardiographic and haemodynamic parameters in a large cohort of patients with documented HFpEF. Methods and results: The REDUCE LAP‐HF II trial randomized 626 patients with ejection fraction ≥40% and exercise pulmonary capillary wedge pressure (PCWP) ≥25 mmHg to atrial shunt or sham procedure. We tested for associations between body mass index (BMI), clinical characteristics, cardiac structural and functional abnormalities, physical limitations, quality of life and outcomes with atrial shunt therapy. Overall, 60.9% of patients had BMI ≥30 kg/m2. As the severity of obesity increased, symptoms (Kansas City Cardiomyopathy Questionnaire score) and 6‐min walk distance worsened. More severe obesity was associated with lower natriuretic peptide levels despite more cardiac remodelling, higher cardiac filling pressures, and higher cardiac output. Lower cut points for E/e′ were needed to identify elevated PCWP in more obese patients. Strain measurements in all four chambers were maintained as BMI increased. Pulmonary vascular resistance at rest and exercise decreased with higher BMI. Obesity was associated with more first and recurrent heart failure events. However, there was no significant interaction between obesity and treatment effects of the atrial shunt. Conclusions: Increasing severity of obesity was associated with greater cardiac remodelling, higher right and left ventricular filling pressures, higher cardiac output and increased subsequent heart failure events. Despite significant obesity, many HFpEF patients have preserved right heart and pulmonary vascular function and thus, may be appropriate candidates for atrial shunt therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure

Author

Borlaug, Barry A., Blair, John, Bergmann, Martin W., Bugger, Heiko, Burkhoff, Dan, Bruch, Leonhard, Celermajer, David S., Claggett, Brian, Cleland, John G. F., Cutlip, Donald E., Dauber, Ira, Eicher, Jean-Christophe, Gao, Qi, Gorter, Thomas M., Gustafsson, Finn, Hayward, Chris, Van der Heyden, Jan, Hasenfuß, Gerd, Hummel, Scott L., Kaye, David M., Komtebedde, Jan, Massaro, Joseph M., Mazurek, Jeremy A., McKenzie, Scott, Mehta, Shamir R., Petrie, Mark C., Post, Marco C., Nair, Ajith, Rieth, Andreas, Silvestry, Frank E., Solomon, Scott D., Trochu, Jean-Noël, Veldhuisen, Dirk J. Van, Westenfeld, Ralf, Leon, Martin B., Shah, Sanjiv J., and Cardiovascular Centre (CVC)

Subjects
Male, Cardiac Catheterization, Pulmonary Circulation, hypertension, pulmonary, hypertension, pulmonary, heart failure, EXERCISE, PRESSURE, Article, Physiology (medical), therapeutics, Humans, Heart Atria, lung diseases, OUTCOMES, REST, Stroke Volume, clinical trial, TIME, Treatment Outcome, PRESERVED EJECTION FRACTION, Female, vascular diseases, Cardiology and Cardiovascular Medicine, INTERATRIAL SHUNT
Abstract

Background: In REDUCE LAP-HF II (A Study to Evaluate the Corvia Medical, Inc IASD System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure), implantation of an atrial shunt device did not provide overall clinical benefit for patients with heart failure with preserved or mildly reduced ejection fraction. However, prespecified analyses identified differences in response in subgroups defined by pulmonary artery systolic pressure during submaximal exercise, right atrial volume, and sex. Shunt implantation reduces left atrial pressures but increases pulmonary blood flow, which may be poorly tolerated in patients with pulmonary vascular disease (PVD). On the basis of these results, we hypothesized that patients with latent PVD, defined as elevated pulmonary vascular resistance during exercise, might be harmed by shunt implantation, and conversely that patients without PVD might benefit. Methods: REDUCE LAP-HF II enrolled 626 patients with heart failure, ejection fraction ≥40%, exercise pulmonary capillary wedge pressure ≥25 mm Hg, and resting pulmonary vascular resistance Results: Compared with patients without PVD (n=382), those with latent PVD (n=188) were older, had more atrial fibrillation and right heart dysfunction, and were more likely to have elevated left atrial pressure at rest. Shunt treatment was associated with worse outcomes in patients with PVD (win ratio, 0.60 [95% CI, 0.42, 0.86]; P =0.005) and signal of clinical benefit in patients without PVD (win ratio, 1.31 [95% CI, 1.02, 1.68]; P =0.038). Patients with larger right atrial volumes and men had worse outcomes with the device and both groups were more likely to have pacemakers, heart failure with mildly reduced ejection fraction, and increased left atrial volume. For patients without latent PVD or pacemaker (n=313; 50% of randomized patients), shunt treatment resulted in more robust signal of clinical benefit (win ratio, 1.51 [95% CI, 1.14, 2.00]; P =0.004). Conclusions: In patients with heart failure with preserved or mildly reduced ejection fraction, the presence of latent PVD uncovered by invasive hemodynamic exercise testing identifies patients who may worsen with atrial shunt therapy, whereas those without latent PVD may benefit.

Published
2022

17. Randomised study for the Optimal Treatment of symptomatic patients with low-gradient severe Aortic valve Stenosis and preserved left ventricular ejection fraction (ROTAS trial)

Author

Galli, Elena, Le Ven, Florent, Coisne, Augustin, Sportouch, Catherine, Le Tourneau, Thierry, Lavie-Badie, Yoan, Bernard, Anne, Eicher, Jean-Christophe, Dreyfus, Julien, Ternacle, Julien, Baleynaud, Serge, Auffret, Vincent, Le Pabic, Estelle, Pibarot, Philippe, Oger, Emmanuel, and Donal, Erwan

Abstract

BackgroundThe best management of symptomatic patients with low-gradient (LG) severe aortic stenosis (AS) and preserved left ventricular ejection fraction (LVEF) has not been established. The Randomised study for the Optimal Treatment of symptomatic patients with low-gradient severe Aortic valve Stenosis (ROTAS) trial aimed to assess the superiority of aortic valve replacement (AVR) versus medical treatment (MT) in this specific group of AS patients.MethodsPatients with symptomatic LG severe AS and preserved LVEF (>50%) underwent dobutamine stress echocardiography and/or CT-aortic calcium score to confirm AS severity and were then randomised 1:1 to AVR or MT. The primary endpoint was a composite of overall death and/or cardiovascular hospitalisation.ResultsThe ROTAS study was stopped early because of insufficient recruitment. In the end, only 52 patients (age 79±7 years; women 54%; NYHA III-IV 27%; median STS score 3.3%) were included in the study. During follow-up (mean: 14±7 months), the primary endpoint occurred in 12 (23%) patients. Compared with MT, AVR was not associated with a significant prognostic benefit (events: 5/26 (19%) vs 7/26 (27%) (HR 0.76, 95% CI 0.24 to 2.39, p=0.63). During follow-up, 11 (42%) patients in the MT group developed class I criteria for AVR or severe symptoms justifying a cross-over to the AVR group.ConclusionsBecause of the small number of included patients and short follow-up the ROTAS trial was underpowered and unable to demonstrate a difference in the study endpoint between treatment arms. In patients in the MT arm, a regular echocardiographic and clinical assessment might be useful to disclose those developing class I indications of AVR or severe AS-related symptoms.Trial registration numberNCT01835028.

Published
2024
Full Text
View/download PDF

18. Feasibility and accuracy of linking a heart failure registry to the national claims database using indirect identifiers

Author

Logeart, Damien, primary, Damy, Thibaud, additional, Doublet, Maxime, additional, Salvat, Muriel, additional, Tribouilloy, Christophe, additional, Bauer, Fabrice, additional, Eicher, Jean-Christophe, additional, Picard, François, additional, Roul, Gérald, additional, Trochu, Jean-Noël, additional, De Groote, Pascal, additional, Bihry, Nicolas, additional, Berthelot, Emmanuelle, additional, Jondeau, Guillaume, additional, Seronde, Marie-France, additional, Roubille, François, additional, and Isnard, Richard, additional

Published
2023
Full Text
View/download PDF

19. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction

Author

Girerd, Nicolas, Von Hunolstein, Jean-Jacques, Pellicori, Pierpaolo, Bayés-Genís, Antoni, Jaarsma, Tiny, Lund, Lars H., Bilbault, Pascal, Boivin, Jean-Marc, Chouihed, Tahar, Costa, Jérôme, Eicher, Jean-Christophe, Fall, Estelle, Kenizou, David, Maillier, Bruno, Nazeyrollas, Pierre, Roul, Gérald, Zannad, Noura, Rossignol, Patrick, and Seronde, Marie-France

Subjects
Heart Failure, Ventricular Dysfunction, Left, Kardiologi, Humans, Cardiac and Cardiovascular Systems, Stroke Volume, Cardiology and Cardiovascular Medicine
Abstract

No abstract available.

Published
2022

20. Impact of the First COVID-19 Wave on French Hospitalizations for Myocardial Infarction and Stroke: A Retrospective Cohort Study

Author

Mariet, Anne-Sophie, primary, Duloquin, Gauthier, additional, Benzenine, Eric, additional, Roussot, Adrien, additional, Pommier, Thibaut, additional, Eicher, Jean-Christophe, additional, Baptiste, Laura, additional, Giroud, Maurice, additional, Cottin, Yves, additional, Béjot, Yannick, additional, and Quantin, Catherine, additional

Published
2022
Full Text
View/download PDF

21. Prognosis of Adults With Isolated Left Ventricular Non-Compaction: Results of a Prospective Multicentric Study

Author

Gerard, Hilla, primary, Iline, Nicolas, additional, Martel, Hélène, additional, Nguyen, Karine, additional, Richard, Pascale, additional, Donal, Erwan, additional, Eicher, Jean-Christophe, additional, Huttin, Olivier, additional, Selton-Suty, Christine, additional, Raud-Raynier, Pascale, additional, Jondeau, Guillaume, additional, Mansencal, Nicolas, additional, Sawka, Caroline, additional, Ader, Flavie, additional, Pruny, Jean-François, additional, Casalta, Anne-Claire, additional, Michel, Nicolas, additional, Donghi, Valeria, additional, Faivre, Laurence, additional, Giorgi, Roch, additional, Charron, Philippe, additional, and Habib, Gilbert, additional

Published
2022
Full Text
View/download PDF

22. Smoking in Patients With Chronic Cardiovascular Disease During COVID-19 Lockdown

Author

Chagué, Frédéric, Boulin, Mathieu, Eicher, Jean-Christophe, Bichat, Florence, Saint-Jalmes, Maïlis, Cransac, Amélie, Soudry, Agnès, Danchin, Nicolas, Laurent, Gabriel, Cottin, Yves, and Zeller, Marianne

Subjects
Cardiology and Cardiovascular Medicine
Abstract

ObjectivesThis cross-sectional study aims to investigate health-related behaviors including tobacco consumption among patients with cardiovascular diseases (CVD), during the first COVID-19-related lockdown.MethodsAfter 5 weeks of COVID-19 lockdown, 220 patients with chronic coronary syndromes (CCS) and 124 with congestive heart failure (CHF) answered a phone questionnaire.ResultsAmong these 344 patients, 43 (12.5%) were current smokers, and none had quit during the lockdown. When compared with non-smokers, smokers were 15 years younger, more often diabetic, more likely to live in an urban than a rural lockdown location, and more often in the CCS cohort (p = 0.011). Smokers described greater psychological impairment, but their rates of decrease in physical activity and of increase in screen time were similar to non-smokers. More than one-third (13/43) increased their tobacco consumption, which was mainly related to stress or boredom, but not driven by media messages on a protective effect of nicotine.ConclusionsDuring the first COVID-19 lockdown, we found a decrease in favorable lifestyle behaviors among patients with CVD. Strikingly, one-third of smokers with CCS or CHF increased their tobacco consumption. Given the major impact of persistent smoking in patients with CVD, this highlights the need for targeted prevention strategies, in particular during such periods.

Published
2022

23. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II):a randomised, multicentre, blinded, sham-controlled trial

Author

Shah, Sanjiv J., Borlaug, Barry A., Chung, Eugene, Cutlip, Donald E., Debonnaire, Philippe, Fail, Peter, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M., Litwin, Sheldon E., Lurz, Philipp, Massaro, Joseph M., Mohan, Rajeev C., Ricciardi, Mark J., Solomon, Scott D., Sverdlov, Aaron L., Swarup, Vijendra, van Veldhuisen, Dirk J., Winkler, Sebastian, Leon, Martin B., Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean Christophe, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, Hass, Moritz, Shah, Sanjiv J., Borlaug, Barry A., Chung, Eugene, Cutlip, Donald E., Debonnaire, Philippe, Fail, Peter, Gao, Qi, Hasenfuß, Gerd, Kahwash, Rami, Kaye, David M., Litwin, Sheldon E., Lurz, Philipp, Massaro, Joseph M., Mohan, Rajeev C., Ricciardi, Mark J., Solomon, Scott D., Sverdlov, Aaron L., Swarup, Vijendra, van Veldhuisen, Dirk J., Winkler, Sebastian, Leon, Martin B., Akar, Joseph, Ando, Jiro, Anzai, Toshihisa, Asakura, Masanori, Bailey, Steven, Basuray, Anupam, Bauer, Fabrice, Bergmann, Martin, Blair, John, Cavendish, Jeffrey, Cikes, Maja, Dauber, Ira, Donal, Erwan, Eicher, Jean Christophe, Flaherty, James, Freixa, Xavier, Gafoor, Sameer, Gertz, Zachary, Gordon, Robert, Guazzi, Marco, Guerrero-Miranda, Cesar, Gupta, Deepak, Gustafsson, Finn, Hadadi, Cyrus, Hakemi, Emad, Handoko, Louis, and Hass, Moritz

Abstract

Background: Placement of an interatrial shunt device reduces pulmonary capillary wedge pressure during exercise in patients with heart failure and preserved or mildly reduced ejection fraction. We aimed to investigate whether an interatrial shunt can reduce heart failure events or improve health status in these patients. Methods: In this randomised, international, blinded, sham-controlled trial performed at 89 health-care centres, we included patients (aged ≥40 years) with symptomatic heart failure, an ejection fraction of at least 40%, and pulmonary capillary wedge pressure during exercise of at least 25 mm Hg while exceeding right atrial pressure by at least 5 mm Hg. Patients were randomly assigned (1:1) to receive either a shunt device or sham procedure. Patients and outcome assessors were masked to randomisation. The primary endpoint was a hierarchical composite of cardiovascular death or non-fatal ischemic stroke at 12 months, rate of total heart failure events up to 24 months, and change in Kansas City Cardiomyopathy Questionnaire overall summary score at 12 months. Pre-specified subgroup analyses were conducted for the heart failure event endpoint. Analysis of the primary endpoint, all other efficacy endpoints, and safety endpoints was conducted in the modified intention-to-treat population, defined as all patients randomly allocated to receive treatment, excluding those found to be ineligible after randomisation and therefore not treated. This study is registered with ClinicalTrials.gov, NCT03088033. Findings: Between May 25, 2017, and July 24, 2020, 1072 participants were enrolled, of whom 626 were randomly assigned to either the atrial shunt device (n=314) or sham procedure (n=312). There were no differences between groups in the primary composite endpoint (win ratio 1·0 [95% CI 0·8–1·2]; p=0·85) or in the individual components of the primary endpoint. The prespecified subgroups demonstrating a differential effect of atrial shunt device treatment on hea

Published
2022

24. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke

Author

Mas, Jean-Louis, Derumeaux, Geneviève, Guillon, Benoît, Massardier, Evelyne, Hosseini, Hassan, Mechtouff, Laura, Arquizan, Caroline, Béjot, Yannick, Vuillier, Fabrice, Detante, Olivier, Guidoux, Céline, Canaple, Sandrine, Vaduva, Claudia, Dequatre-Ponchelle, Nelly, Sibon, Igor, Garnier, Pierre, Ferrier, Anna, Timsit, Serge, Robinet-Borgomano, Emmanuelle, Sablot, Denis, Lacour, Jean-Christophe, Zuber, Mathieu, Favrole, Pascal, Pinel, Jean-François, Apoil, Marion, Reiner, Peggy, Lefebvre, Catherine, Guérin, Patrice, Piot, Christophe, Rossi, Roland, Dubois-Randé, Jean-Luc, Eicher, Jean-Christophe, Meneveau, Nicolas, Lusson, Jean-René, Bertrand, Bernard, Schleich, Jean-Marc, Godart, François, Thambo, Jean-Benoit, Leborgne, Laurent, Michel, Patrik, Pierard, Luc, Turc, Guillaume, Barthelet, Martine, Charles-Nelson, Anaïs, Weimar, Christian, Moulin, Thierry, Juliard, Jean-Michel, and Chatellier, Gilles

Published
2017
Full Text
View/download PDF

25. Incomplete Timothy syndrome secondary to a mosaic mutation of the CACNA1C gene diagnosed using next-generation sequencing

Author

Baurand, Amandine, Falcon-Eicher, Sylvie, Laurent, Gabriel, Villain, Elisabeth, Bonnet, Caroline, Thauvin-Robinet, Christel, Jacquot, Caroline, Eicher, Jean-Christophe, Gourraud, Jean-Baptiste, Schmitt, Sébastien, Bézieau, Stéphane, Giraud, Mathilde, Dumont, Solenne, Kuentz, Paul, Probst, Vincent, Burguet, Antoine, Kyndt, Florence, and Faivre, Laurence

Published
2017
Full Text
View/download PDF

26. COVID-19 Lockdown in Patients with Chronic Diseases: A Cross-Sectional Study

Author

Boulin, Mathieu, primary, Cransac-Miet, Amélie, additional, Maynadié, Marc, additional, Volot, Fabienne, additional, Creuzot-Garcher, Catherine, additional, Eicher, Jean-Christophe, additional, Chagué, Frédéric, additional, Ksiazek, Eléa, additional, Beltramo, Guillaume, additional, Bonniaud, Philippe, additional, Moreau, Thibault, additional, Bonnotte, Bernard, additional, Sales-Wuillemin, Edith, additional, Soudry-Faure, Agnès, additional, Zeller, Marianne, additional, and Cottin, Yves, additional

Published
2022
Full Text
View/download PDF

27. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

Author

Shah, Sanjiv J, primary, Borlaug, Barry A, additional, Chung, Eugene S, additional, Cutlip, Donald E, additional, Debonnaire, Philippe, additional, Fail, Peter S, additional, Gao, Qi, additional, Hasenfuß, Gerd, additional, Kahwash, Rami, additional, Kaye, David M, additional, Litwin, Sheldon E, additional, Lurz, Philipp, additional, Massaro, Joseph M, additional, Mohan, Rajeev C, additional, Ricciardi, Mark J, additional, Solomon, Scott D, additional, Sverdlov, Aaron L, additional, Swarup, Vijendra, additional, van Veldhuisen, Dirk J, additional, Winkler, Sebastian, additional, Leon, Martin B, additional, Akar, Joseph, additional, Ando, Jiro, additional, Anzai, Toshihisa, additional, Asakura, Masanori, additional, Bailey, Steven, additional, Basuray, Anupam, additional, Bauer, Fabrice, additional, Bergmann, Martin, additional, Blair, John, additional, Cavendish, Jeffrey, additional, Chung, Eugene, additional, Cikes, Maja, additional, Dauber, Ira, additional, Donal, Erwan, additional, Eicher, Jean-Christophe, additional, Fail, Peter, additional, Flaherty, James, additional, Freixa, Xavier, additional, Gafoor, Sameer, additional, Gertz, Zachary, additional, Gordon, Robert, additional, Guazzi, Marco, additional, Guerrero-Miranda, Cesar, additional, Gupta, Deepak, additional, Gustafsson, Finn, additional, Hadadi, Cyrus, additional, Hakemi, Emad, additional, Handoko, Louis, additional, Hass, Moritz, additional, Hausleiter, Jorg, additional, Hayward, Christopher, additional, Hickey, Gavin, additional, Hummel, Scott, additional, Hussain, Imad, additional, Isnard, Richard, additional, Izumi, Chisato, additional, Jondeau, Guillaume, additional, Juneman, Elizabeth, additional, Kinugawa, Koichiro, additional, Kipperman, Robert, additional, Krakowiak, Bartek, additional, Krim, Selim, additional, Larned, Joshua, additional, Lewis, Gregory, additional, Lipsic, Erik, additional, Magalski, Anthony, additional, Mazimba, Sula, additional, Mazurek, Jeremy, additional, McGrady, Michele, additional, Mckenzie, Scott, additional, Mehta, Shamir, additional, Mignone, John, additional, Morsli, Hakim, additional, Nair, Ajith, additional, Noel, Thomas, additional, Orford, James, additional, Parikh, Kishan, additional, Patterson, Tiffany, additional, Penicka, Martin, additional, Petrie, Mark, additional, Pieske, Burkert, additional, Post, Martijn, additional, Raake, Philip, additional, Romero, Alicia, additional, Ryan, John, additional, Saito, Yoshihiko, additional, Sakamoto, Takafumi, additional, Sakata, Yasushi, additional, Samara, Michael, additional, Satya, Kumar, additional, Sindone, Andrew, additional, Starling, Randall, additional, Trochu, Jean-Noël, additional, Upadhya, Bharathi, additional, van der Heyden, Jan, additional, van Empel, Vanessa, additional, Varma, Amit, additional, Vest, Amanda, additional, Wengenmayer, Tobias, additional, Westenfeld, Ralf, additional, Westermann, Dirk, additional, Yamamoto, Kazuhiro, additional, and Zirlik, Andreas, additional

Published
2022
Full Text
View/download PDF

28. Telemonitoring versus standard care in heart failure: a randomised multicentre trial

Author

Galinier, Michel, Roubille, François, Berdagué, Philippe, Brierre, Gilles, Cantie, Philippe, Dary, Patrick, Ferradou, Jean‐Marc, Fondard, Olivier, Labarre, Jean Philippe, Mansourati, Jacques, Picard, François, Ricci, Jean‐Etienne, Salvat, Muriel, Tartière, Lamia, Ruidavets, Jean‐Bernard, Bongard, Vanina, Delval, Cécile, Lancman, Guila, Pasche, Hélène, Ramirez‐Gil, Juan Fernando, Pathak, Atul, Machecourt, Jacques, Valeix, Bernard, Royer, Thierry, Louvard, Yves, Aboyans, Victor, Beard, Thierry, Cheggour, Saïda, Cottin, Yves, Delarche, Nicolas, Eicher, Jean‐Christophe, Faure, Antoine, Gibelin, Pierre, Gosse, Philippe, Inamo, Jocelyn, Lescure‐Ducay, Maryse, Litalien, Jean, Milhau, Sabine, Pouchelon, Elisabeth, Prunier, Fabrice, Salloum, Antoine, Aloun, Jocelyn Souk, Tartière, Jean‐Michel, Taudou, Marie‐José, Thuny, Franck, Tribouilloy, Christophe, Service de cardiologie [Toulouse], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), MSP Beziers, Centre Hospitalier de Beziers, Centre Hospitalier Intercommunal Castres-Mazamet, Clinique Pasteur [Toulouse], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), CHU Bordeaux [Bordeaux], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Toulouse [Toulouse], Air Liquide Santé International, Service de Pharmacologie Clinique, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Hôpital Purpan [Toulouse], CHU Limoges, Service de Cardiologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre hospitalier de Pau, Hôpital Pasteur [Nice] (CHU), Hôpital Saint-André, Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Laboratoire de Protection et Remodelage du Myocarde (PMRM), Université d'Angers (UA)-Université d'Angers (UA), Hôpital Sainte-Musse, Service de cardiologie, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service de Cardiologie [Amiens], CHU Amiens-Picardie, Service Cardiologie [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service Pharmacologie Clinique [CHU Toulouse], and Pôle Santé publique et médecine publique [CHU Toulouse]

Subjects
Male, Relative risk reduction, Telemonitoring, medicine.medical_specialty, Class iii, 030204 cardiovascular system & hematology, Rate ratio, 03 medical and health sciences, 0302 clinical medicine, Primary outcome, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Standard care, Internal medicine, Hospitalisation, medicine, Humans, Editorial Comments, Aged, Aged, 80 and over, Heart Failure, business.industry, Hazard ratio, Standard of Care, Patient education, Body weight, Middle Aged, medicine.disease, Telemedicine, Confidence interval, 3. Good health, Hospitalization, Heart failure, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, Cardiology and Cardiovascular Medicine, business, Editorial Comment
Abstract

International audience; Aims: The aim was to assess the effect of a telemonitoring programme vs. standard care (SC) in preventing all‐cause deaths or unplanned hospitalisations in heart failure (HF) at 18 months.Methods and results: OSICAT was a randomised, multicentre, open‐label French study in 937 patients hospitalised for acute HF ≤12 months before inclusion. Patients were randomised to telemonitoring (daily body weight measurement, daily recording of HF symptoms, and personalised education) (n = 482) or to SC (n = 455). Mean ± standard deviation number of events for the primary outcome was 1.30 ± 1.85 for telemonitoring and 1.46 ± 1.98 for SC [rate ratio 0.97, 95% confidence interval (CI) 0.77–1.23; P = 0.80]. In New York Heart Association (NYHA) class III or IV HF, median time to all‐cause death or first unplanned hospitalisation was 82 days in the telemonitoring group and 67 days in the SC group (P = 0.03). After adjustment for known predictive factors, telemonitoring was associated with a 21% relative risk reduction in first unplanned hospitalisation for HF [hazard ratio (HR) 0.79, 95% CI 0.62–0.99; P = 0.044); the relative risk reduction was 29% in patients with NYHA class III or IV HF (HR 0.71, 95% CI 0.53–0.95; P = 0.02), 38% in socially isolated patients (HR 0.62, 95% CI 0.39–0.98; P = 0.043), and 37% in patients who were ≥70% adherent to body weight measurement (HR 0.63, 95% CI 0.45–0.88; P = 0.006).Conclusion: Telemonitoring did not result in a significantly lower rate of all‐cause deaths or unplanned hospitalisations in HF patients. The pre‐specified subgroup results suggest the telemonitoring approach improves clinical outcomes in selected populations but need further confirmation.

Published
2020

31. Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis

Author

Fischer, Kilian, primary, Lellouche, Nicolas, additional, Damy, Thibaud, additional, Martins, Raphaël, additional, Clementy, Nicolas, additional, Bisson, Arnaud, additional, Lesaffre, François, additional, Espinosa, Madeline, additional, Garcia, Rodrigue, additional, Degand, Bruno, additional, Serzian, Guillaume, additional, Jourda, François, additional, Huttin, Olivier, additional, Guichard, Jean‐Baptiste, additional, Devilliers, Hervé, additional, Eicher, Jean‐Christophe, additional, Laurent, Gabriel, additional, and Guenancia, Charles, additional

Published
2021
Full Text
View/download PDF

32. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness

Author

Damy, Thibaud, Costes, Bruno, Hagège, Albert A., Donal, Erwan, Eicher, Jean-Christophe, Slama, Michel, Guellich, Aziz, Rappeneau, Stéphane, Gueffet, Jean-Pierre, Logeart, Damien, Planté-Bordeneuve, Violaine, Bouvaist, Hélène, Huttin, Olivier, Mulak, Geneviève, Dubois-Randé, Jean-Luc, Goossens, Michel, Canoui-Poitrine, Florence, and Buxbaum, Joel N.

Published
2016
Full Text
View/download PDF

34. Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study

Author

Chirouze, Catherine, Curlier, Elodie, Descottes-Genon, Cécile, Hoen, Bruno, Patry, Isabelle, Vettoretti, Lucie, Chavanet, Pascal, Eicher, Jean-Christophe, Greusard, Marie-Christine, Neuwirth, Catherine, Péchinot, André, Piroth, Lionel, Célard, Marie, Cornu, Catherine, Delahaye, François, Hadid, Malika, Rausch, Pascale, Coma, Audrey, Galtier, Florence, Géraud, Philippe, Jean-Pierre, Hélène, Le Moing, Vincent, Sportouch, Catherine, Reynes, Jacques, Aissa, Nejla, Doco-Lecompte, Thanh, Goehringer, François, Keil, Nathalie, Letranchant, Lorraine, Malela, Hepher, May, Thierry, Selton-Suty, Christine, Bedos, Nathalie, Lavigne, Jean-Philippe, Lechiche, Catherine, Sotto, Albert, Duval, Xavier, Habensus, Emila Ilic, Iung, Bernard, Leport, Catherine, Longuet, Pascale, Ruimy, Raymond, Bellissant, Eric, Donnio, Pierre-Yves, Le Gac, Fabienne, Michelet, Christian, Revest, Matthieu, Tattevin, Pierre, Thebault, Elise, Alla, François, Braquet, Pierre, Erpelding, Marie-Line, Minary, Laetitia, Bès, Michèle, Etienne, Jérôme, Tristan, Anne, Vandenesch, François, Van Belkum, Alex, Vanwamel, Willem, Braquet, P., Alla, F., Cornu, C., Goehringer, F., Piroth, L., Chirouze, C., Revest, M., Lechiche, C., Duval, X., and Le Moing, V.

Published
2016
Full Text
View/download PDF

35. Temporal Relationship between Atrial Fibrillation and Heart Failure Development Analysis from a Nationwide Database

Author

Cottin, Yves, primary, Maalem Ben Messaoud, Brahim, additional, Monin, Antoine, additional, Guilleminot, Pierre, additional, Bisson, Arnaud, additional, Eicher, Jean-Christophe, additional, Bodin, Alexandre, additional, Herbert, Julien, additional, Juillière, Yves, additional, Zeller, Marianne, additional, and Fauchier, Laurent, additional

Published
2021
Full Text
View/download PDF

36. Early and short‐term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD‐HF)

Author

Logeart, Damien, primary, Berthelot, Emmannuelle, additional, Bihry, Nicolas, additional, Eschalier, Romain, additional, Salvat, Muriel, additional, Garcon, Philippe, additional, Eicher, Jean‐Christophe, additional, Cohen, Ariel, additional, Tartiere, Jean‐Michel, additional, Samadi, Alireza, additional, Donal, Erwan, additional, deGroote, Pascal, additional, Mewton, Nathan, additional, Mansencal, Nicolas, additional, Raphael, Pierre, additional, Ghanem, Nachwan, additional, Seronde, Marie‐France, additional, Chavelas, Christophe, additional, Rosamel, Yann, additional, Beauvais, Florence, additional, Kevorkian, Jean‐Philippe, additional, Diallo, Abdourahmane, additional, Vicaut, Eric, additional, and Isnard, Richard, additional

Published
2021
Full Text
View/download PDF

37. First symptoms and health care pathways in hospitalized patients with acute heart failure: ICPS2 survey. A report from the Heart Failure Working Group (GICC) of the French Society of Cardiology

Author

Beauvais, Florence, primary, Tartière, Lamia, additional, Pezel, Théo, additional, Motet, Chloé, additional, Aumont, Marie‐Claude, additional, Baudry, Guillaume, additional, Eicher, Jean‐Christophe, additional, Galinier, Michel, additional, Gellen, Barnabas, additional, Guihaire, Julien, additional, Legallois, Damien, additional, Lequeux, Benoit, additional, Mika, Delphine, additional, Mouquet, Frederic, additional, Salvat, Muriel, additional, Taieb, Charles, additional, Zorès, Florian, additional, Berthelot, Emmanuelle, additional, and Damy, Thibaud, additional

Published
2021
Full Text
View/download PDF

40. Natural history of functional tricuspid regurgitation: impact of cardiac output

Author

Chen, Elisabeth, primary, L’official, Guillaume, additional, Guérin, Anne, additional, Dreyfus, Julien, additional, Lavie-Badie, Yoan, additional, Sportouch, Catherine, additional, Eicher, Jean-Christophe, additional, Maréchaux, Sylvestre, additional, Le Tourneau, Thierry, additional, Oger, Emmanuel, additional, and Donal, Erwan, additional

Published
2021
Full Text
View/download PDF

41. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study

Author

Logeart, Damien, Isnard, Richard, Resche-Rigon, Matthieu, Seronde, Marie-France, de Groote, Pascal, Jondeau, Guillaume, Galinier, Michel, Mulak, Geneviève, Donal, Erwan, Delahaye, François, Juilliere, Yves, Damy, Thibaud, Jourdain, Patrick, Bauer, Fabrice, Eicher, Jean-Christophe, Neuder, Yannick, Trochu, Jean-Noël, Chantal, Ache Papillon, Nadia, Aissaoudi, François, Aupetit Jean, Christian, Baietto, Noël, Baille, Serge, Baleynaud, Jacques, Ballout, Claude, Barnay, Fabrice, Bauer, Bechetoille, Mohammed, Belhameche, Loïc, Belle, Sandrine, Bentzinger, Alain, Bergere, Philippe, Bernadet, Marie, Perron Jean, François, Bernasconi, Samia, Berranen, Annick, Bineau-Jorisse, Michel, Serrano, Christian, Boureux, Salim, Boutalba, Erik, Bouvier, Marc, Bouvier Jean, Françoise, Bragard Marie, Philippe, Brunel, Roland, Carlioz, Christophe, Charniot Jean, Christophe, Chavelas, Saïda, Cheggour, Pascal, Chevalet, Vlad, Ciobotaru, René, Codjia, Alain, Cohen Solal, Patrick, Coulon, Daniel, Czitrom, Nicolas, Dahdal, Philippe, De Corbiere, Pascal, De Groote, Olivier, De Sauniere, France, Deforet Marie, Alain, Lassabe, Michel, Mansour, François, Delahaye, Michel, Chuzeville, Arnaud, Dellinger, Jacques, Denis, Gilles, Dentan, Michèle, Desruennes, Sylvain, Destrac, Claude, Dib Jean, Rodies, Dimitriou, Philippe, Doazan Jean, Erwan, Donal, Pierre, Matali, Pierre, Dos Santos, Roland, Sananes, Jacques, Dujardin Jean, Hervé, Gallois, Eric, Durand, Michel, Desnos, Sophie, Durand, Florence, Durup, Laurent, Dutoit, J-C, Eicher, Abdellatif, El Hallak, Mariam, Elkohen, Elodie, Faveau, Michèle, Escande, Jean, Ettori, Laurent, Fauchier, François, Maillot, Jean-Pierre, Favier, Bertrand, Fontan, Patrick, Friocourt, Philippe, Fromage, Michel, Galinier, Daniel, Galley, Erik, Garbarz, Philippe, Garcon, Daniel, Garnier, Cédric, Gaxatte, Frédéric, Georger, Renaud, Gervais, Nachwan, Ghanem, Géraldine, Gibault, Clément, Charbonnel, Pierre, Gibelin, Patrice, Brocker, Michel, Gofard, Mohand, Goudjil, Gilbert, Habib, Maryline, Hamdan-Challe, Olivier, Hanon, Michèle, Pinson, Luc, Hittinger, David, Houpe, Agnes, Hyverts, Eva, Inorowicz, Richard, Isnard, Adi, Issa, Muntaser P, Jamal, Luc, Jannin-Manificat, Guillaume, Jondeau, Patrick, Jourdain, Marc, Joussen Jean, Alain, Juillard, Yves, Juilliere, David, Kenizou, Barbara, Lambert, Skander, Khechine, Robin, Zelinsky, Pierre, Lagorce, Maryse, Lescure, Pierre, Lantelme, Thierry, Laperche, Fabrice, Larrazet, Evelyne, Laurent, Philippe, Le Metayer, Patrick, Assyag, Julien, Lemoine, Rémy, Lepori, Benoit, Lequeux, Guillaume, Lhernault, Christine, Machuron, Dominique, Magnin, Nam, Mai, Hamid, Makki, Mounia, Malou, J Jacques, Marier, Jean-Pierre, Maroni, Michel, Martelet, Colette, Matagrin, Nicolas, Coquerel, Mestre-Fernandes, Damien, Metz, Christophe, Meune, Laurent, Michel, Sandrine, Migran, Olivier, Milleron, Catherine, Mimran, Christian, Montagnier, Christophe, Moreau, Yannick, Neuder, Laurent, Orion, Blandine, Ouattara, Joël, Belmin, Eric, Perchicot, Sandrine, Peyrot, Laurent, Poirette, Philippe, Pon-Gabrielsen, Isabelle, Poulain, Fabrice, Prunier, Mamy, Randriamora, Pierre, Raphael, Charles, Raynaud Jean, Guy, Rebuffat, Michel, Remond, Franck, Revel, François, Roubille, Rémi, Sabatier, Raïf, Sader, Robert, Sal, Carole, Saudubray, France, Seronde Marie, François-Xavier, Soto, Jocelyn, Souk Aloun, Benoit, Spillemaecker, Adel, Srour, Yves, Tabet Jean, Michel, Tartiere Jean, Guy, Thourot, Thierry, Tibi, Christophe, Tribouilloy, Noël, Trochu Jean, Eric, Verbrugge, François, Vinchon, and Khelil, Yaici

Published
2013
Full Text
View/download PDF

43. Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis.

Author

Fischer, Kilian, Lellouche, Nicolas, Damy, Thibaud, Martins, Raphaël, Clementy, Nicolas, Bisson, Arnaud, Lesaffre, François, Espinosa, Madeline, Garcia, Rodrigue, Degand, Bruno, Serzian, Guillaume, Jourda, François, Huttin, Olivier, Guichard, Jean‐Baptiste, Devilliers, Hervé, Eicher, Jean‐Christophe, Laurent, Gabriel, and Guenancia, Charles

Subjects
CARDIAC pacing, CARDIAC amyloidosis
Abstract

Aims: Cardiac resynchronization therapy (CRT) is highly effective in dilated cardiomyopathy (DCM) patients with impaired left ventricular ejection fraction (LVEF) and left bundle block branch. In cardiac amyloidosis (CA) patients, left ventricular dysfunction and conduction defects are common, but the potential of CRT to improve cardiac remodelling and survival in this particular setting remains undefined. We investigated cardiovascular outcomes in CA patients after CRT implantation in terms of CRT echocardiographic response and major cardiovascular events (MACEs). Methods and results: Our retrospective study included 47 CA patients implanted with CRT devices from January 2012 to February 2020, in nine French university hospitals (77 ± 6 years old, baseline LVEF 30 ± 8%) compared with propensity‐matched (1:1 for age, LVEF at implantation, and CRT indication) DCM patients with a CRT device. CA patients had lower rates of CRT response (absolute delta LVEF ≥ 10%) compared with DCM patients (36% vs. 70%, P = 0.002). After multivariate Cox analysis, CA was independently associated with MACE (hospitalization for heart failure/cardiovascular death) [hazard ratio (HR) 3.73, 95% confidence interval (CI) 1.85–7.54, P < 0.001], along with the absence of CRT response (HR 3.01, 95% CI 1.56–5.79, P = 0.001). The presence of echocardiographic CRT response (absolute delta LVEF ≥ 10%) was the only predictive factor of MACE‐free survival in CA patients (HR 0.36, 95% CI 0.15–0.86, P = 0.002). Conclusion: Compared with a matched cohort of DCM patients, CA patients had a lower rate of CRT response and consequently a worse cardiovascular prognosis after CRT implantation. However, CRT could be beneficial even in CA patients given that CRT response was associated with better cardiac outcomes in this population. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Cardiomyopathy due to PRDM16 mutation: First description of a fetal presentation, with possible modifier genes

Author

Delplancq, Geoffroy, primary, Tarris, Georges, additional, Vitobello, Antonio, additional, Nambot, Sophie, additional, Sorlin, Arthur, additional, Philippe, Christophe, additional, Carmignac, Virginie, additional, Duffourd, Yannis, additional, Denis, Charlotte, additional, Eicher, Jean Christophe, additional, Chevarin, Martin, additional, Millat, Gilles, additional, Khallouk, Bouchra, additional, Rousseau, Thierry, additional, Falcon‐Eicher, Sylvie, additional, Vasiljevic, Alexandre, additional, Harizay, Fara T., additional, Thauvin‐Robinet, Christel, additional, Faivre, Laurence, additional, and Kuentz, Paul, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results